Diphtheria toxoid

Highest phase reached
Drug type
Vaccine component
First approval year

First approval year
Listing at source
Listed
Highest phase reached

Drug type
Vaccine component
Drug name
Diphtheria toxoid

  • diphtheria toxoid component of hexacima
  • Diphtheria toxoid component of hexacima
  • diphtheria toxoid component of hexavac
  • Diphtheria toxoid component of hexavac
  • diphtheria toxoid component of hexyon
  • Diphtheria toxoid component of hexyon
  • diphtheria toxoid component of infanrix hepb
  • Diphtheria toxoid component of infanrix hepb
  • diphtheria toxoid component of infanrix hexa
  • Diphtheria toxoid component of infanrix hexa
  • diphtheria toxoid component of infanrix penta
  • Diphtheria toxoid component of infanrix penta
  • diphtheria toxoid component of primavax
  • Diphtheria toxoid component of primavax
  • diphtheria toxoid component of quintanrix
  • Diphtheria toxoid component of quintanrix
  • diphtheria toxoid component of triacelluvax
  • Diphtheria toxoid component of triacelluvax
  • diphtheria toxoid component of tritanrix hepb
  • Diphtheria toxoid component of tritanrix hepb
  • diphtheria toxoid component of vaxelis
  • Diphtheria toxoid component of vaxelis

  • diphtheria toxoid
  • Diphtheria toxoid
  • tetanus toxoid diphtheria toxoid and pertussis vaccine
  • Tetanus-Diphtheria Toxoid (Td)

ATC classification codes
  • J07AF01
Sources for recorded values
ChEMBL ID
CHEMBL2109121
RxNorm IDs (RxCUI)
  • 798304

First in class
No
Orphan designation
No

Mechanisms of action

  • Mechanism
    Diphtheria toxoid vaccine antigen
    Action type
    VACCINE_ANTIGEN
    Target
    Diphtheria toxoid

  • Condition
    Leukemia, Lymphocytic, Chronic, B-Cell
    Highest recorded phase
    2
    Condition identifier
    EFO:0000095
    Subject identifier
    D015451
  • Condition
    Glioblastoma
    Highest recorded phase
    2
    Condition identifier
    EFO:0000519
    Subject identifier
    D005909
  • Condition
    Alopecia Areata
    Highest recorded phase
    3
    Condition identifier
    EFO:0004192
    Subject identifier
    D000506
  • Condition
    Severe Dengue
    Highest recorded phase
    3
    Condition identifier
    EFO:0004227
    Subject identifier
    D019595
  • Condition
    Meningococcal Infections
    Highest recorded phase
    3
    Condition identifier
    EFO:0004249
    Subject identifier
    D008589
  • Condition
    Vaccination
    Highest recorded phase
    4
    Condition identifier
    EFO:0004292
    Subject identifier
    D014611
  • Condition
    Dengue
    Highest recorded phase
    3
    Condition identifier
    EFO:0005547
    Subject identifier
    D003715
  • Condition
    Tetanus
    Highest recorded phase
    4
    Condition identifier
    EFO:0005593
    Subject identifier
    D013742
  • Condition
    Meningitis, Meningococcal
    Highest recorded phase
    3
    Condition identifier
    EFO:1001040
    Subject identifier
    D008585
  • Condition
    Brain Neoplasms
    Highest recorded phase
    1
    Condition identifier
    MONDO:0001657
    Subject identifier
    D001932

  • Condition identifier
    EFO_0000519
    Highest recorded phase
    2
  • Condition identifier
    EFO_0000650
  • Condition identifier
    EFO_0004192
    Highest recorded phase
    3
  • Condition identifier
    EFO_0004197
  • Condition identifier
    EFO_0004227
    Highest recorded phase
    2
  • Condition identifier
    EFO_0004249
    Highest recorded phase
    3
  • Condition identifier
    EFO_0005549
  • Condition identifier
    EFO_0005593
  • Condition identifier
    EFO_0007450
  • Condition identifier
    EFO_0009444
    Highest recorded phase
    3
  • Condition identifier
    EFO_1001040
    Highest recorded phase
    3
  • Condition identifier
    HP_0001662
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0004948
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005077
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0005344
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0005504
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0005526
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0017373
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0018177
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0021042
    Highest recorded phase
    2

Reported adverse events

  • Event
    vertical infection transmission
    Reports
    1
    Reporting signal score
    8.39775

Dose
0.5 mL
Route
Intramuscular
How often
At 2, 4, 6, and 15-18 months of age

  • Discard unused portion
  • Reconstitute immediately before administration
  • Use immediately after reconstitution

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

Related records

Trials (172)

Approved for (1)

In development for (8)

Other linked conditions (4)